Banking on Shanghai's biotech boom, this Eli Lilly-backed player grabs $100M to push next-gen I/O therapies
Every six months for the past two years or so, five renowned scientists and biotech vets — David Shen of NGM Bio, Arlene Sharpe and Vijay Kuchroo of Harvard, Juno co-founder Phil Greenberg and University of Chicago’s Tom Gajewski — would meet. There (most recently at Napa Valley over wine), as a scientific advisory board, they would offer advice to a biotech startup based an ocean away in Shanghai, on their quest to uncover new targets and new antibody therapeutics for immuno-oncology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.